EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieKlinische Studie (Phase II)

Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension

Mason W Freeman, Yuan-Di Halvorsen, William Marshall, Mackenzie Pater, Jon Isaacsohn, Catherine Pearce, Brian Murphy, Nicholas Alp, Ajay Srivastava, Deepak L Bhatt iD, Morris J Brown iD, BrigHTN Investigators

New England Journal of Medicine · 02.02.2023 · 388 (5) · 395-405

DOI: 10.1056/nejmoa2213169 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift New England Journal of Medicine, erschienen am 02.02.2023. Verfasst von Mason W Freeman und 11 weiteren Autor:innen. Beteiligte Einrichtung: From CinCor Pharma (M.W.F., Y.-D.H., W.M., C.P.) and Brigham and Women's Hospital, Harvard Medical School (D.L.B.) - both in Boston; CinRx Pharma (M.…. Hauptthemen laut MEDLINE: Antihypertensive Agents, Cytochrome P-450 CYP11B2, Hypertension. Die Arbeit wurde bisher 403-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Medical Research Council, CinCor Pharma, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antihypertensive AgentsCytochrome P-450 CYP11B2HypertensionHumansAldosteroneBlood PressureDouble-Blind Method

Substanzen

AldosteroneAntihypertensive AgentsCytochrome P-450 CYP11B2

Autor:innen und Institutionen

  • From CinCor Pharma (M.W.F., Y.-D.H., W.M., C.P.) and Brigham and Women's Hospital, Harvard Medical School (D.L.B.) - both in Boston; CinRx Pharma (M.P., J.I., B.M.) and Medpace (N.A., A.S.) - both in Cincinnati; and the…

ORCID-Profile: Deepak L Bhatt, Morris J Brown

Förderung

  • Medical Research Council
  • CinCor Pharma, Inc.

Zitieren

APA

Freeman, M. W., Halvorsen, Y. D., Marshall, W., Pater, M., Isaacsohn, J., Pearce, C., Murphy, B., Alp, N., Srivastava, A., Bhatt, D. L., Brown, M. J., & BrigHTN Investigators (2023). Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension. New England Journal of Medicine, 388(5), 395-405. https://doi.org/10.1056/nejmoa2213169

Vancouver

Freeman MW, Halvorsen YD, Marshall W, Pater M, Isaacsohn J, Pearce C, et al. Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension. New England Journal of Medicine. 2023;388(5):395-405. doi:10.1056/nejmoa2213169

BibTeX
@article{Freeman2023,
  author = {Freeman, Mason W and Halvorsen, Yuan-Di and Marshall, William and Pater, Mackenzie and Isaacsohn, Jon and Pearce, Catherine and Murphy, Brian and Alp, Nicholas and Srivastava, Ajay and Bhatt, Deepak L and Brown, Morris J and BrigHTN Investigators, BrigHTN Investigators},
  title = {Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension},
  journal = {New England Journal of Medicine},
  year = {2023},
  volume = {388},
  number = {5},
  pages = {395--405},
  doi = {10.1056/nejmoa2213169}
}
Kostenlos starten →